David Corteville, MD
Cardiovascular Disease · Rochester, NYNPI 1699867788
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $66,409 of the $87,265 with a category attached, or 76.1%. AstraZeneca accounts for 81.9% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $34,021, more than ten times the $245 reported in 2019. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $445.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$71K
- Boston Scientific$5K
- Edwards Lifesciences$4K
- Novartis$2K
- Abbott$2K
- Novo Nordisk$459
- plus $2K from 20 others
Across 7 payments — averaging $2759.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$16K
- Surmodics, Inc.$3K
What the payments were for
- Consulting fees$66,40976%
- Speaking & faculty fees$5,0006%
- Travel & lodging$10,98313%
- Food & beverage$4,8556%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 72 | $71,449 |
| Boston Scientific | 7 | $5,403 |
| Edwards Lifesciences | 16 | $4,398 |
| Novartis | 20 | $2,049 |
| Abbott | 17 | $1,918 |
| Novo Nordisk | 11 | $459 |
| Boehringer Ingelheim | 12 | $457 |
| Lilly USA, LLC | 3 | $199 |
| Siemens Medical Solutions USA, Inc. | 2 | $138 |
| Scpharmaceuticals Inc. | 2 | $122 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Amgen | 5 | $93 |
| Johnson & Johnson | 4 | $73 |
| Merck | 3 | $61 |
| Kestra Medical Technology Services, Inc. | 1 | $55 |
| Lantheus Medical Imaging, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $38 |
| Irhythm Technologies, Inc. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $26 |
| Pfizer | 1 | $24 |
| Bracco Diagnostics Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,265 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 362 | $485,673 |
| EliquisApixaban | 265 | $325,534 |
| EntrestoSacubitril/Valsartan | 186 | $260,874 |
| FarxigaDapagliflozin Propanediol | 188 | $223,694 |
| OzempicSemaglutide | 174 | $205,609 |
| Repatha SureclickEvolocumab | 113 | $110,877 |
| MounjaroTirzepatide | 46 | $52,158 |
| XareltoRivaroxaban | 26 | $39,062 |
| TrulicityDulaglutide | 22 | $33,268 |
| WegovySemaglutide | 17 | $22,895 |
| Praluent PenAlirocumab | 22 | $11,368 |
| Ezetimibe | 274 | $10,450 |
| Atorvastatin Calcium | 518 | $8,601 |
| Metoprolol Succinate | 410 | $7,764 |
| Rosuvastatin Calcium | 343 | $6,644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $457 | $485,673362 claims |
| PfizerEliquis | $24 | $325,534265 claims |
| NovartisEntresto | $2,049 | $260,874186 claims |
| Novo NordiskOzempic, Wegovy | $459 | $228,504191 claims |
| AstraZenecaFarxiga | $71,449 | $223,694188 claims |
| Lilly USA, LLCMounjaro, Trulicity | $199 | $85,42668 claims |
| Johnson & JohnsonXarelto | $73 | $39,06226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Rochester
- James EichelbergerRochester$332K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.